- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Unmet Needs In Agitation Associated With Alzheimer’s Dementia (AAD)
This is a virtual event for PsychU members in North Carolina and South Carolina.
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlates in AAD. Describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Miranda Fisher, PhD
Medical Science Liaison

Amica Simmons-Yon, PharmD, PhD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Chris Brodie, PhD (OPDC)
Medical Science Liaison
Speakers Miranda Fisher, PhD; Amica Simmons-Yon, PharmD, PhD; and Chris Brodie, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)